Resources Archive | Aldeyra Therapeutics, Inc.

Scientific Paper

Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease

External Link

DAVID CLARK, JOSEPH TAUBER, JOHN SHEPPARD, AND TODD C. BRADY
American Journal of Ophthalmology, Volume 226, 22 – 31

Posters and Presentations

Poster Presentation – A Phase 2 Clinical Trial of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in an Allergen Chamber Model of Allergic Conjunctivitis (American Academy of Ophthalmology 2020 Annual Meeting)

PDF (802.22 KB)

November 2020

Posters and Presentations

COVID 19 Development Update

PDF (868.14 KB)

May 2020

Posters and Presentations

2020 Research & Development Day

PDF (3.76 MB)

February 2020

Posters and Presentations

Poster Presentation of ALLEVIATE Phase 3 Allergic Conjunctivitis Clinical Trial of Topical Ocular Reproxalap (American Academy of Ophthalmology 2019 Annual Meeting)

PDF (649.05 KB)

October 2019

Posters and Presentations

Podium Presentation of Dry Eye Disease 2b Clinical Trial of Reproxalap (2019 ARVO Annual Meeting) – May 2019

PDF (2.47 MB)

May 2019

Posters and Presentations

Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis – March 2019

PDF (1.44 MB)

March 2019

Posters and Presentations

2019 Research & Development Day with Updates on Research Programs – February 2019

PDF (6.72 MB)

February 2019

Posters and Presentations

Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial – September 2018

PDF (3.28 MB)

September 2018

Posters and Presentations

Poster Presentation of ADX-103 Activity in Model of Diabetic Macular Edema (Association for Research in Vision and Ophthalmology 2018 Annual Meeting) – May 2018

PDF (241.60 KB)

May 2018